A new drug have been launched for the HSDD treatment
Pharmaceutical company Boeringer Engleheim have announced that they have launched a drive to push marketing for their new drug for treating hypoactive sexual desire disorder (HSDD), Flibanserin.
Euro RSCG have been commissioned by the company to deal with communications with health professionals for them, in order to promote the treatment as a solution for women suffering from HSDD.
Read more on A new drug have been launched for the HSDD treatment…